<DOC>
	<DOCNO>NCT00113113</DOCNO>
	<brief_summary>Cancer patient liver renal dysfunction treat rubitecan capsule define maximum tolerated dose dose-limiting toxicity patient population , perform pharmacokinetic study rubitecan patient population .</brief_summary>
	<brief_title>Study Rubitecan Cancer Patients With Renal Hepatic Dysfunction</brief_title>
	<detailed_description />
	<mesh_term>Rubitecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>The patient least 18 year age . The patient histologically cytologically proven malignancy recurrent refractory standard treatment standard therapy . The patient measurable disease . The patient sufficiently recover acute toxic effect previous chemotherapy , radiotherapy ( le 3 week prior randomization ) , and/or immunotherapy . The patient 's estimate life expectancy least 8 week . The patient National Cancer Institute Common Toxicity Criteria ( NCI CTC ) Performance Status 0 2 . The patient adequate bone marrow function . The patient must active central nervous system ( CNS ) metastases . The patient serious , uncontrolled intercurrent illness infection . The patient receive antiretroviral therapy ( HAART ) HIV infection . The patient pregnant nursing .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2005</verification_date>
	<keyword>rubitecan</keyword>
	<keyword>Orathecin</keyword>
	<keyword>9-nitrocamptothecin</keyword>
	<keyword>solid tumor</keyword>
	<keyword>organ dysfunction</keyword>
	<keyword>renal dysfunction</keyword>
	<keyword>hepatic dysfunction</keyword>
	<keyword>RFS 2000</keyword>
</DOC>